skin cancer
Conditions
Interventions
None listed
Sponsors
NKI-AVL
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Metastatic melanoma; (sub)cutaneous metastases
Exclusion criteria
Exclusion criteria: Hemophilia en other blood coagulation disorders
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The presence of melanoma-reactive T lymphocytes will be determined in the tumor tissue and in the blood of each patient. These T lymphocytes will subsequently be tested for the ability to lyse melanoma cells in the metastasis and/or melanocytes in the skin, using the skin/tumor explant system. The analyses in this system also incorporate the influence of the tissue microenvironment on the T cell functionality. | — |
Secondary
| Measure | Time frame |
|---|---|
| Our ex vivo in situ tumor and skin explant system is the first to integrate the multidimensionality of human tumor-host interactions, and can therefore predict the efficacy of these interactions in vivo more accurately than in vitro assays based on rather artificial interactions between cells in suspension. This study provides insight in the defects in individual patients that cause failure of tumor regression by immunotherapy and may lead to novel strategies to overcome these defects and improved immunotherapy of melanoma in the future. | — |
Countries
Netherlands
Outcome results
None listed